At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
CS-1008 (humanized anti-DR5 antibody) +1 moredrug
Likely dose
CS-1008 (humanized anti-DR5 antibody) 8mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating CS-1008 (humanized anti-DR5 antibody) and gemcitabine for Pancreatic Cancer. Completed, enrolled 65 participants across 12 sites.
Detailed Summary
Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionAug 2010
TodayJul 2026
First PostedAug 27, 2007
Enrollment StartAug 15, 2007
Primary CompletionAug 20, 2010
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 18.8 years ago
Interventions
CS-1008 (humanized anti-DR5 antibody)drug
CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
gemcitabinedrug
Gemcitabine - 1000mg/meter sq